Advertisement

Topics

Boehringer Ingelheim Pharmaceuticals, Inc Company Profile

08:24 EDT 24th September 2017 | BioPortfolio

Boehringer Ingelheim Corporation is the U.S. member of the Boehringer Ingelheim worldwide group of companies dedicated to the discovery, development, manufacture and marketing of innovative human and animal health care products.
It is the principal U.S. licensee of Boehringer Ingelheim GmbH, an international chemical and pharmaceutical firm that develops, produces and sells pharmaceuticals, veterinary medicines and biologicals, agricultural chemical products and fine, specialty chemicals in more than 45 companies around the world. Worldwide sales for the Boehringer Ingelheim group of companies were $10.2 billion in 2004. The world's largest privately held pharmaceutical enterprise, Boehringer Ingelheim GmbH employs over 36,000 people.

Boehringer Ingelheim Corporation is the parent of a group of U.S. companies that produce ethical pharmaceuticals, natural health products, veterinary products and fine chemicals. Collectively, the U.S. Boehringer Ingelheim companies employ more than 7,200 people.

Location

900 Ridgebury Road/P.O. Box 368
Ridgefield
Connecticut
6877
United States of America

Contact

Phone: (203) 798-9988
Fax: (800) 243-0127
Email: koconno4@rdg.boehringer-ingelheim.com


News Articles [1676 Associated News Articles listed on BioPortfolio]

Boehringer Ingelheim Upping Manufacturing Capacity

NewsBoehringer Ingelheim breaks ground on $217 million expansion of Fremont, California manufacturing facility. Expansion will triple capacity, add nearly 300 new jobs.

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of mu...

Boehringer Ingelheim starts phase III interchangeability trial for adalimumab biosimilar

Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) announced on 27 July 2017 that the first patient had been enrolled into the phase III VOLTAIRE‑X interchangeability stu...

Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand.  The new Phase I trials initi...

Boehringer Ingelheim mit gutem Wachstum im ersten Halbjahr 2017

Ingelheim (ots) - - Querverweis: Bildmaterial wird über obs versandt und ist abrufbar unter http://www.presseportal.de/bilder - Boehringer Ingelheim zieht eine positive Bilanz nach dem ersten Halbj.....

Boehringer Ingelheim’s adalimumab biosimilar ‘equivalent’ to Humira

Germany-based biologicals specialist Boehringer Ingelheim (Boehringer) announced on 14 June 2017 positive results from its pivotal phase III study of its candidate adalimumab biosimilar.

Boehringer Ingelheim initiates phase IIa study of liver disease NASH compound

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American phase IIa trial in NASH with BI 1467335 (formerly known as PX...

Boehringer Ingelheim Initiates Study on Biosimilar Candidate to Humira

NewsBoehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira. Study is first in the U.S. to investigate an interchangeabi...

Drugs and Medications [326 Associated Drugs and Medications listed on BioPortfolio]

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Dulcolax balance [Boehringer Ingelheim Pharmaceuticals Inc]

Boehringer-Ingelheim Consumer Health Care Products Dulcolax Balance® Drug Facts

Pradaxa [Boehringer Ingelheim Pharmaceuticals Inc.]

These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules for o...

PubMed Articles [159 Associated PubMed Articles listed on BioPortfolio]

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelhei...

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Clinical Trials [211 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions

The objective of this study is to evaluate the comparative bioavailability between Tamsulosin Hydrochloride 0.4 mg Capsules (Teva Pharmaceuticals USA) and Flomax® 0.4 mg Capsules (Boehrin...

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Companies [1314 Associated Companies listed on BioPortfolio]

Boehringer Ingelheim Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group ...

Boehringer Ingelheim Pharmaceuticals, Inc

Boehringer Ingelheim Corporation is the U.S. member of the Boehringer Ingelheim worldwide group of companies dedicated to the discovery, development, manufacture and marketing of innovative human and ...

Boehringer Ingelheim Pharmaceuticals, Inc.

Metabolism is one of Boehringer Ingelheim's core R&D areas and diabetes is one of the indications at the center of interest within the company's global research network. Boehringer Ingelheim is commit...

Boehringer Ingelheim Limited

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146...

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...

More Information about "Boehringer Ingelheim Pharmaceuticals, Inc" on BioPortfolio

We have published hundreds of Boehringer Ingelheim Pharmaceuticals, Inc news stories on BioPortfolio along with dozens of Boehringer Ingelheim Pharmaceuticals, Inc Clinical Trials and PubMed Articles about Boehringer Ingelheim Pharmaceuticals, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boehringer Ingelheim Pharmaceuticals, Inc Companies in our database. You can also find out about relevant Boehringer Ingelheim Pharmaceuticals, Inc Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record